Fennec Pharmaceuticals logo

Fennec Pharmaceuticals

FENC | NASDAQ
Chart Builder DCF Calculator
$12.76
+$1.14 (+9.81%)
At close: Nov 16, 2026, 4:00 PM ET
$12.70
-$0.06 (-0.47%)
After-hours: Nov 16, 2026, 7:30 PM ET
+9.81%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
60.8
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #129/1021 (Top 13%)

Key Statistics

Market Data

Market Cap $450.49M
1D Range
11.82 12.88
52W Range
5.77 12.88

Valuation (TTM)

PE 2.28K
PB 9.16
EV/EBITDA 151.74

Valuation (NTM)

Forward PE 35.21
Forward PEG -1.44
Price Target $16.00
Loading financial charts...

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment i...

Sector Healthcare
Industry Biotechnology
Employees 35
IPO Date Sep 15, 2017
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 12, 2026
EPS
$0.12
Beat +25.00%
REV
$19.61M
Beat +3.92%
Next Earnings
Mar 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$16.00
Upside
+25.39%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.